Enspryng Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to limited treatment options for nmosd, increased awareness of autoimmune neurology disorders, success of monoclonal antibody therapies, improved diagnostic accuracy, rising specialty neurology centers.

The growth in the forecast period can be attributed to expansion of biologics in neurology, increasing diagnosis of rare demyelinating diseases, demand for long term relapse prevention, favorable biologic reimbursement trends, ongoing neuroimmunology research. Major trends in the forecast period include interleukin-6 targeted neurology therapies, growth of rare neuroimmunology treatments, shift toward long acting injectable biologics, expansion of personalized autoimmune care, increased focus on relapse prevention.

The increasing prevalence of multiple sclerosis is expected to drive the growth of the enspryng market in the coming years. Multiple sclerosis (MS) is a chronic disease of the central nervous system (CNS) that affects the brain and spinal cord. The rise in MS cases is largely due to improved diagnosis through advanced imaging techniques and better reporting, which allow earlier and more accurate detection. Enspryng (satralizumab) treats relapsing forms of multiple sclerosis by blocking the interleukin-6 receptor, reducing inflammation and preventing nerve damage. It is administered via monthly subcutaneous injections. For example, in May 2024, the Multiple Sclerosis Society, a UK-based charity for people affected by MS, reported that over 7,100 people are diagnosed with MS each year, with 71% being women, making women 2.5 times more likely than men to develop the condition. Therefore, the rising prevalence of multiple sclerosis is supporting the growth of the enspryng market.

Increasing investment in healthcare is also expected to drive the growth of the enspryng market. Healthcare investment refers to the allocation of financial resources, including capital and operational funding, toward healthcare technologies, services, and initiatives. The rapid adoption of telemedicine and AI-driven diagnostics is driving significant investment, as these technologies promise improved patient outcomes and operational efficiency. Such investment has supported the development, regulatory approval, manufacturing, and global distribution of enspryng, ensuring accessibility for patients with NMOSD. For example, in November 2024, the Health Foundation, a UK-based independent charity, reported that planned healthcare spending will rise from approximately $221.1 billion (£177.9 billion) in 2023/24 to $237.4 billion (£190.1 billion) in 2024/25 and $250.1 billion (£200.5 billion) in 2025/26, representing an average annual real-term growth of 3.3% since 2023/24. Therefore, increasing healthcare investment is supporting the growth of the enspryng market.

The key trend in the Enspryng market is the attainment of forerunner designation to speed up the development of treatments for autoimmune diseases with high unmet medical needs, specifically myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and autoimmune encephalitis (AIE), facilitating faster regulatory review and earlier patient access. Forerunner designation is awarded to innovative drug candidates that satisfy specific criteria, offering prioritized consultation and accelerated pre-market review processes. For example, in March 2023, Chugai Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, announced that Enspryng (satralizumab), a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody, received forerunner designation from Japan’s Ministry of Health, Labour and Welfare for the anticipated indications in MOGAD and AIE. This designation is intended to ensure timely availability of Enspryng for patients awaiting new treatment options, particularly for conditions with no existing approved therapies.

Major companies operating in the enspryng market are F. Hoffmann-La Roche AG.

North America was the largest region in the enspryng market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the enspryng market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the enspryng market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have influenced the enspryng market by increasing costs related to biologic raw materials, injectable device components, and global logistics. Specialty neurology clinics and hospital pharmacies in import dependent regions face higher procurement expenses. These pressures can impact treatment affordability and access. At the same time, tariffs are driving localized biologics manufacturing initiatives. This strengthens regional supply chains and long term treatment continuity.

The enspryng market research report is one of a series of new reports that provides enspryng market statistics, including enspryng industry global market size, regional shares, competitors with a enspryng market share, detailed enspryng market segments, market trends and opportunities, and any further data you may need to thrive in the enspryng industry. This enspryng market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Enspryng (satralizumab) is a monoclonal antibody used to treat neuromyelitis optica spectrum disorder (NMOSD) in adults with aquaporin-4 antibodies. It works by inhibiting the interleukin-6 receptor to reduce inflammation and is administered subcutaneously every four weeks following a loading phase. Common side effects include headache and an increased risk of infections.

The primary indications for enspryng are neuromyelitis optica spectrum disorder (NMOSD) and generalized myasthenia gravis (gMG). NMOSD is a rare autoimmune disease that primarily affects the central nervous system, especially the optic nerves and spinal cord. The drug can be used across different age groups and seropositivity profiles and is distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The enspryng market consists of sales of products including satralizumab and prefilled syringes and monotherapy products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.